ArticleTrials2022
M
Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03981445 (A Multi-site Multi-Setting Randomized Controlled Trial), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-site Multi-Setting Randomized Controlled Trial (RCT) of Integrated HIV Prevention and HCV Care for People Who Inject Drugs (PWID)
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Experiences of Integration of HIV, Hepatitis, and Sexually Transmitted Infection Services Across Different Countries Worldwide: A Scoping Review.Health science reports · 2026Article
- Integration of HIV, Hepatitis B, and C, and sexually transmitted infections services: A scoping review of the benefits and challenges.PloS one · 2026Article
- Approaches to Offering Hepatitis C Treatment at Syringe Services Programs in the United States: A Scoping Review.Open forum infectious diseases · 2025Review
- HCV Treatment Outcomes in PWID: Impact of Addiction History on SVR12.Microorganisms · 2024Article
- Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.Addiction science & clinical practice · 2024Article
- Article
- Identifying barriers and facilitators to COVID-19 vaccination uptake among People Who Use Drugs in Canada: a National Qualitative Study.Harm reduction journal · 2023Article
- A study protocol for Project I-Test: a cluster randomized controlled trial of a practice coaching intervention to increase HIV testing in substance use treatment programs.Research square · 2023Article
- Correction: MTrials · 2022Article
- Integrating harm reduction and addiction care in HIV prevention among persons who inject drugs in the United States-a narrative review.Therapeutic advances in infectious diseaseReview
Corrections and comments
- Erratum issuedCorrection: M2022
Authors and funding
20 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundOpioid use is escalating in North America and comes with a multitude of health consequences, including HIV and hepatitis C virus (HCV) outbreaks among persons who inject drugs (PWID). HIV pre-exposure prophylaxis (PrEP) and HCV treatment regimens have transformative potential to address these co-occurring epidemics. Evaluation of innovative multi-modal approaches, integrating harm reduction, opioid agonist therapy (OAT), PrEP, and HCV treatment is required. The aim of this study is to assess the effectiveness of an on-site integrated care model where delivery of PrEP and HCV treatment for PWID takes places at syringe service programs (SSP) and OAT programs compared with referring PWID to clinical services in the community through a patient navigation model and to examine how structural factors interact with HIV prevention adherence and HCV treatment outcomes.
methodsThe Miami-Montreal Hepatitis C and Pre-Exposure Prophylaxis trial (M DISCUSSION: The results of this study have the potential to demonstrate the effectiveness and cost-effectiveness of offering PrEP and HCV treatment in healthcare venues frequently attended by PWID. Testing the intervention in two urban centers with high disease burden among PWID, but with different healthcare system dynamics, will increase generalizability of findings.
trial registrationClinicaltrials.gov NCT03981445 . Trial registry name: Integrated HIV Prevention and HCV Care for PWID (M2HepPrEP). Registration date: June 10, 201.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.